Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And Milestone Payments Of Up To $592M Per Product
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech has entered into an agreement with Merck for two preclinical vaccine candidates, receiving $3.2M upfront and potential future payments. Merck has the option to license these candidates, with milestone payments up to $592M per product.
September 26, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evaxion Biotech's agreement with Merck could significantly boost its financials with an upfront payment and potential milestone payments, enhancing its market position.
The agreement with Merck provides immediate financial inflow and potential for substantial future payments, which could improve Evaxion's financial stability and market perception.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Merck's option to license Evaxion's vaccine candidates could enhance its vaccine portfolio, with potential milestone payments indicating a significant investment in future products.
Merck's involvement in licensing preclinical candidates from Evaxion suggests a strategic investment in expanding its vaccine offerings, which could positively impact its future product pipeline.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80